ArticleJournal of translational medicine2025
CircPRDM5-mediated regulation of miR-433-3p and HDAC6 in Parkinson's disease: a novel neuroprotective axis.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CircRNAs: Novel biomarkers and therapeutic targets for diseases of the central nervous system.Biochemistry and biophysics reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons, leading to motor and non-motor symptoms. Despite advances in PD research, the molecular mechanisms underlying its pathogenesis remain incompletely understood. Recent studies have highlighted the potential role of circular RNAs (circRNAs) in neurodegenerative diseases. This study aims to investigate the regulatory role of circPRDM5 in PD, focusing on its interactions with miR-433-3p and HDAC6.
methodsBioinformatics tools were used to identify circPRDM5 and its potential interaction with miR-433-3p. Peripheral blood samples were collected from 20 PD patients and healthy controls to measure circPRDM5, miR-433-3p, and HDAC6 expression. For in vivo studies, an MPTP-induced PD mouse model was established, and circPRDM5 knockdown was achieved via tail vein injections of shRNA constructs. Behavioral tests, histological analysis, and immunohistochemistry were used to evaluate motor function and neuronal integrity. In vitro, SH-SY5Y neuroblastoma cells were treated with MPP⁺ to induce PD-like characteristics, followed by transfection with circPRDM5 knockdown constructs and miR-433-3p mimics or inhibitors. Cell viability, lactate dehydrogenase (LDH) release, apoptosis, and autophagy were measured through CCK-8 assay, flow cytometry, western blotting, and immunofluorescence.
resultsCircPRDM5 expression was significantly elevated in PD patients and MPTP-induced PD mice, with knockdown of circPRDM5 alleviating motor deficits and neuronal damage in vivo. In vitro, circPRDM5 knockdown in SH-SY5Y cells reduced MPP
conclusionsThis study reveals that circPRDM5 promotes neuronal damage in PD by sponging miR-433-3p and upregulating HDAC6, contributing to apoptosis and autophagy. Knockdown of circPRDM5 reduces PD-like symptoms in both cellular and animal models, providing a potential therapeutic target for PD. Targeting the circPRDM5/miR-433-3p/HDAC6 axis may offer new opportunities for disease-modifying treatments in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.